Pyrroloquinoxaline derivatives as high-affinity and selective 5-HT3 receptor agonists: Synthesis, further structure-activity relationships, and biological studies

Journal of Medicinal Chemistry

Volumn 42, Issue 21, 1999, Pages 4362-4379

  Campiani, Giuseppe ^a   Morelli, Elena ^b   Gemma, Sandra ^b   Nacci, Vito ^b   Butini, Stefania ^b   Hamon, Michel ^e   Novellino, Ettore ^c   Greco, Giovanni ^c   Cagnotto, Alfredo ^d   Goegan, Mara ^d   Cervo, Luigi ^d   Valle, Fabio Dalla ^d   Fracasso, Claudia ^d   Caccia, Silvio ^d   Mennini, Tiziana ^d  

^a UNIVERSITY OF SALERNO   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^e PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PYRROLE DERIVATIVE; QUINOXALINE DERIVATIVE; SEROTONIN 3 AGONIST;

ANALGESIC ACTIVITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG CONFORMATION; DRUG DISTRIBUTION; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG UPTAKE; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; RAT; RECEPTOR AFFINITY; RECEPTOR DENSITY; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTI-ANXIETY AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BLOOD-BRAIN BARRIER; BRAIN; GUANIDINE; GUINEA PIGS; HYBRID CELLS; LIGANDS; MALE; PYRROLES; QUINOXALINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, SEROTONIN; RECEPTORS, SEROTONIN, 5-HT3; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0032749316     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm990151g     Document Type: Article

References (34)

1. Baumgarten, H. G.; Gothert, M. Serotoninergic Neurons and 5-HT Receptors in the CNS; Springer-Verlag: Berlin, 1997.
2. Saxena, P. R.; de Vries, P.; Villalon, C. M. 5-HT1-like Receptors: a Time to Bid Goodbye. Trends Pharmacol Sci. 1998, 19, 311-316 and references therein.
3. Veyrat-Follet, C.; Farinotti, R.; Palmer, J. L. Physiology of Chemotherapy-Induced Emesis and Antiemetic Therapy. Predictive Models for Evaluation of New Compounds. Drugs 1997, 53, 206-234.
4. 3 Receptors. Pharmacol. Ther. 1990, 47, 181-202.
5. 3 Receptors. J. Neurochem. 1994, 62, 2254-2261.
6. 3 Receptor Agonists Based on a Pyrroloquinoxaline Structure. J. Med. Chem. 1997, 40, 3670-3678.
7. (b) Dunitz, J. D.; Tylor, R. Organic Fluorine Hardly Ever Accepts Hydrogen Bonds. Chemistry-A Eur. J. 1997, 3, 89-98.
8. 3 Receptor Ligands and Substance P. J. Neurochem. 1993, 60, 2059-2067.
9. 3 Receptor Sites. Med. Chem. Res. 1996, 6, 81-101.
10. 3 Receptors. Part 1. Synthesis and Biological Evaluation of Piperazinopyrrolothienopyrazines. J. Med. Chem. 1996, 39, 2068-2080.
11. 3 Receptors. 2. Synthesis and Biological Evaluation of Piperazinopyridopyrrolopyrazines, Piperazinopyrroloquinoxalines, and Piperazinopyridopyrroloquinoxalines. J. Med. Chem. 1997, 40, 1808-1819.
12. (a) Davey, D. D.; Erhardt, P. W.; Cantoe, E. H.; Greenberg, S. S.; Ingebretsen, W. R.; Wiggins, J. Novel Compounds Possessing potent cAMP and cGMP Phosphodiesterase Inhibitory Activity. Synthesis and Cardiovascular Effects of a Series of Imidazo[1,2-a]quinoxalinones and Imidazo[1,5-a]quinoxalinones, and Their Aza Analogues. J. Med. Chem. 1991, 34, 2671-2677.
13. (b) Vogt, B. R. U.S. Patent 4,112,098, Sept 5, 1978, Appl. 842,718, Oct 17, 1977; Chem. Abstr. 1979, 90, 137848k.
14. (b) Vogt, B. R. U.S. Patent 4,112,098, Sept 5, 1978, Appl. 842,718, Oct 17, 1977; Chem. Abstr. 1979, 90, 137848k.
15. Akira, M.; Watanabe, T. Japanese Patent 74 27,877, July 22, 1974, Appl. 70 129,461, Dec 30, 1970; Chem. Abstr. 1975, 82, 156398q.
16. Akira, M.; Watanabe, T. Japanese Patent 74 27,877, July 22, 1974, Appl. 70 129,461, Dec 30, 1970; Chem. Abstr. 1975, 82, 156398q.
17. (a) Campiani, G.; Nacci, V.; Corelli, F.; Anzini, M. Polycondensed Heterocycles. VII. A Convenient Synthesis of Pyrrolo[1,2-a]-quinoxaline Derivatives by Intramolecular Aromatic Nucleophilic Displacement. Synth. Commun. 1991, 21, 1567-1576.
18. (b) 2-(Bromomethyl)thiophene, 2-(bromomethyl)furan, 2-bromo-5-(bromomethyl)thiophene, and 2-bromo-5-(bromomethyl)furan were prepared according to the following reference: Clarke, J. A.; Meth-Cohn, O. Alkylthiophenes as Versatile Synthetic Precursor. Part I. A New Route to 3-Thienyl Aldehydes and Ketones. Tetrahedron Lett. 1975, 52, 4705-4708.
19. (a) Lumma, W. C.; Randall, W. C.; Cresson, E. L.; Huff, G. R.; Hartman, R. D.; Lyon, T. F. Piperazinylimidazo[1,2-a]pyrazines with Selective Affinity for In Vitro α-Adrenergic Receptor Subtypes. J. Med. Chem. 1983, 26, 357-363.
20. (b) Norton, P. P. An Unexpected Aminolysis in the Synthesis of 5-Substituted 3-(1H-Tetrazol-5-yl)pyrazolo[1,5-a]quinazolines. J. Heterocycl. Chem. 1989, 26, 713-716.
21. (a) De Lean, K. W.; Munson, P. J.; Rodbard, D. Simultaneous Analysis of Families of Sigmoidal Curves: Application to Bioassay, Radioligand Assay, and Physiological Dose-Response Curves. Am. J. Physiol. 1978, 235, E97-E102.
22. (b) Davis, A. M.; Teague, S. J. Hydrogen Bonding, Hydrophobic Interactions, and Failure of the Rigid Receptor Hypothesis. Angew. Chem., Int. Ed. 1999, 38, 736-749.
23. 3 Binding Sites in the Rat Cerebral Cortex and NG108-15 Clonal Cells. Biochem. Pharmacol. 1990, 40, 1541-1550.
24. Crawley, J. N.; Goodwin, F. K. Preliminary Report of a Simple Animal Behavior Model for the Anxiolytic Effects of Benzodiazepines. Pharmacol. Biochem. Behav. 1980,13, 167-170.
25. Crawley, J. N. Neuropharmacology Specificity of a Simple Animal Model for the Behavioral Actions of Benzodiazepines. Pharmacol. Biochem. Behav. 1981, 15, 695-699.
26. 3 Receptor Antagonist. Br. J. Pharmacol. 1988, 93, 985-993.
27. Costall, B.; Jones, B. J.; Kelly, M. E.; Naylor, R. J.; Tomkins, D. M. Exploration of Mice in a Black and White Test Box: Validation as a Model of Anxiety. Pharmacol. Biochem. Behav. 1989, 32, 777-785.
28. 3 Receptor Antagonist. Neurosci. Lett. 1988, 95, 313-317.
29. 3 Receptors Modulates Spinal Nociceptive Reflexes. Brain Res. 1990, 510, 12-16.
30. 3 Receptor-mediated Antinociception: Possible Release of GABA. J. Neurosci. 1991, 11, 1881-1888.
31. (a) Caccia, S.; Garattini, S. 1-Arylpiperazines as Active Metabolites of (4-Substituted Aryl-1-piperazinyl)alkyl Heterocyclic Drugs. Acta Pharmacol. Yugosl. 1990, 40, 441-460.
32. (b) The n-octanol/ water log P values of compounds 20b,l,u,v,ee were calculated using the ClogP program, version 2.0, Biobyte Corp. (Claremont, CA).
33. 3 Receptor Antagonists Based on the Arylpiperazine Skeleton: Synthesis, Structure, Biological Activity, and Comparative Molecular Field Analysis Studies. J. Med. Chem. 1995, 38, 2692-2704.
34. 50) of an Enzymatic Reaction. Biochem. Pharmacol. 1973, 22, 3099-3108.